Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26210527 | 0.94 | POLRMT (0.31) | POLRMTTMPRSS2 | |
| SCHEMBL26224766 | 0.94 | POLRMT (0.31) | POLRMTTMPRSS2 | |
| SCHEMBL26210004 | 0.92 | RIPK1 (0.32) | POLRMTTMPRSS2DOT1LRIPK1 | |
| SCHEMBL26223819 | 0.92 | POLRMT (0.32) | POLRMTTMPRSS2 | |
| SCHEMBL26227558 | 0.92 | POLRMT (0.32) | POLRMTTMPRSS2DOT1LRIPK1 | |
| SCHEMBL26223816 | 0.91 | RIPK1 (0.32) | POLRMTTMPRSS2RIPK1 | |
| SCHEMBL26210052 | 0.91 | POLRMT (0.31) | POLRMTTMPRSS2 | |
| SCHEMBL26213567 | 0.90 | POLRMT (0.34) | POLRMTTMPRSS2DOT1L | |
| SCHEMBL26209836 | 0.90 | CYP17A1 (0.32) | POLRMTTMPRSS2DOT1LCSNK2A2CSNK2A1 | |
| SCHEMBL25607768 | 0.89 | POLRMT (0.34) | POLRMTTMPRSS2DOT1LRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | POLRMT 16/4885TMPRSS2 112/4885DOT1L 2112/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | POLRMT 16/4885TMPRSS2 112/4885DOT1L 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.